The Role of AI in Empowering Early Lung Cancer Detection & Transforming Patient Outcomes
“Lung cancer remains the single most common etiology of cancer-related mortality globally, with most patients diagnosed at advanced stages when treatment efficacy is limited. Detecting lung cancer earlier can significantly improve survival rates, with a greater than 90% survival rate when treatment commences at stage 1.”
ACS awards grant to Hollings pulmonologist to improve lung cancer biomarker testing at community hospitals
“The American Cancer Society has awarded an MUSC Hollings Cancer Center pulmonologist a career development grant to begin research on a logistical question that could improve care for lung cancer patients at community hospitals across South Carolina.”
FDA Grants Fast Track Designation to ABD-147 for Small Cell Lung Cancer
“The FDA granted fast track designation to Abdera Therapeutics’ ABD-147 as treatment for extensive stage small cell lung cancer (SCLC) who have progressed on or after platinum-based chemotherapy. The drug is a next-generation precision radiopharmaceutical that delivers Actinium-225 to solid tumors that express the DLL3 protein.”
Detecting lung cancer early with sugar-sensing nanotech
“For such a common disease, lung cancer can be hard to spot. In the early stages you probably won’t even know you’ve got a problem. But by the time you investigate that persistent cough, your livelihood may already hinge on a range of expensive, invasive treatments. Quan Zhou and Dr Richard Lobb say it doesn’t have to be this way – and they’ve got a sugar-sensing piece of technology that proves it.”
New Imaging Detects Deadly Lung and Prostate Cancers, May Improve Treatment
“A new imaging technique developed at Memorial Sloan Kettering Cancer Center (MSK) shows promise for detecting deadly forms of lung cancer and prostate cancer. The technology uses a radioactive particle that binds to a ligand (molecule) on cancer cells called DLL3, making the cells more visible on PET scans. The DLL3 ligand is especially prominent in small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC), which are aggressive types of the disease.”
Real-World Challenges in Cancer Screening: Understanding Data Sources
“In a recent interview with The American Journal of Managed Care®, Jessica K. Paulus, ScD, senior director of real-world research, Ontada, a business of McKesson, and a trained epidemiologist, addressed challenges in the non–small cell lung cancer space (NSCLC) that include advanced disease at presentation and trends seen in real-world data for these patients.”
Moffitt Researchers Develop Synthesis Method to Enhance Access to Cancer-Fighting Withanolides
“TAMPA, Fla. — Withanolides, a class of naturally occurring compounds found in plants, have long been a focus of cancer research due to their ability to inhibit cancer cell growth, induce cell death and prevent metastasis. These compounds are important in developing new cancer treatments. However, the difficulty of obtaining enough of these compounds from plants has hindered research and therapeutic development.”
Back in Spotlight, Incredibly Youthful Newsman John Stossel, 77, Beat Lung Cancer & Quickly Returned To Work— Early Detection Is Key
“TV presenter John Stossel was diagnosed with lung cancer back in 2016 and underwent surgery remove it. Stossel thankfully didn’t further treatment for the disease, which he credits his “overanxious wife” for leading to him to detecting it early on, and he returned to work soon.”
Slowing inflammation may boost immunotherapy’s effectiveness against advanced lung cancer
“Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a clinical trial led by investigators at the Abramson Cancer Center at the Perelman School of Medicine.
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
“On Wednesday, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) and Merck & Co Inc’s (NYSE:MRK) patritumab deruxtecan (HER3-DXd) for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.”
Blood test developed by KU researchers can detect early-stage lung cancer
“Biosensor technology can detect lung cancer in blood when it is still curable and could be used to screen large populations at risk for the disease.”
Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer
“High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group (CCTG), showed Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo in early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) after complete tumour resection in patients whose tumours express PD-L1 on 25% or more tumour cells.”
